Quick Answer
IO Biotech, Inc. reported Cash and Equivalents of $60.03 million for fiscal year 2024.
IO Biotech, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2024 | $60.03M | -58.1% |
| 2023 | $143.19M | +0.4% |
| 2022 | $142.59M | -32.6% |
| 2021 | $211.53M | +6112.4% |
| 2020 | $3.40M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $30.66M | -61.8% | +9.0% |
| June 30, 2025 | $28.13M | -72.1% | -24.1% |
| March 31, 2025 | $37.09M | -68.6% | -38.2% |
| December 31, 2024 | $60.03M | -58.1% | -25.1% |
| September 30, 2024 | $80.19M | -51.6% | -20.4% |
| June 30, 2024 | $100.75M | -8.5% | -14.6% |
| March 31, 2024 | $117.98M | -8.2% | -17.6% |
| December 31, 2023 | $143.19M | +0.4% | -13.5% |
- IO Biotech, Inc. showed a decrease of -58.1% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2020–2024 period, IO Biotech, Inc.’s cash and equivalents has grown by 1663.0% (from $3.40 million to $60.03 million).
- The most recent figure is from IO Biotech, Inc.’s fiscal year 2024 report (Form 10-K), filed with the SEC on March 31, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: